Cybin Inc. (NASDAQ:HELP – Get Free Report) insider Eric So bought 95,000 shares of Cybin stock in a transaction dated Tuesday, September 1st. The shares were bought at an average cost of $11.80 per share, for a total transaction of $1,121,000.00. Following the completion of the transaction, the insider owned 4,265,014 shares of the company’s stock, valued at approximately $50,327,165.20. This trade represents a 2.28% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Cybin Stock Performance
Shares of NASDAQ HELP opened at $13.68 on Thursday. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.53 and a beta of 0.63. The stock has a 50 day moving average price of $9.70 and a 200 day moving average price of $6.81. Cybin Inc. has a 52-week low of $3.76 and a 52-week high of $14.35.
Cybin (NASDAQ:HELP – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Analysts forecast that Cybin Inc. will post -2.95 earnings per share for the current year.
Hedge Funds Weigh In On Cybin
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on HELP shares. Wall Street Zen upgraded Cybin from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Wells Fargo & Company started coverage on shares of Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target for the company. Finally, TD Cowen upped their price target on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Cybin presently has a consensus rating of “Buy” and a consensus price target of $48.60.
Check Out Our Latest Stock Analysis on HELP
About Cybin
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Read More
- Five stocks we like better than Cybin
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
